Atara Biotherapeutics Executive Compensation (FY25)
ATRA · Executive and director compensation, fiscal 2024 to 2025
The Atara Biotherapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 5, 2026Latest filing (8-K): June 12, 2026
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
78 figures on this page: 70 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — AnhCo Nguyen: $1,573,716 → $1,068,069 (32.1% lower)
Say-on-pay support: 98.6% → 98.8% (0.2 points higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Atara Biotherapeutics' chief executive and what were they paid?
Total compensation for AnhCo Nguyen, President and Chief Executive Officer, came to $1,068,069 in fiscal 2025. Nguyen's total moved 32.1% lower from the $1,573,716 reported for fiscal 2024.
What was Atara Biotherapeutics' say-on-pay result?
The say-on-pay proposal drew 98.8% of votes cast for or against in favor at the meeting held June 9, 2026 for fiscal 2025.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
AnhCo Nguyen President and Chief Executive Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Eric Hyllengren Former Executive Vice President, Chief Financial Officer and Chief Operating Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
AnhCo Nguyen President and Chief Executive Officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Eric Hyllengren Former Executive Vice President, Chief Financial Officer and Chief Operating Officer Departed during or after this year | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Eric Hyllengren | RSU | ◇ | — | — | ◇ | — | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| AnhCo Nguyen | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/01/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/01/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as RSUs and Stock Options (1:1 ratio).
Stock ownership guideline: 3x base salary for non-employee directors
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 9, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 10, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 10, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 31, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 23, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 8, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 16, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | June 27, 2019 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Atara Biotherapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
78 figures on this page: 70 cited to the filing that reported them, 8 calculated from figures it prints.
70 cited to the filing
8 calculated from the filing
Documents cited
- 0001213900-26-068264
- 0001193125-26-1772852025 Summary Compensation Table · EXECUTIVE COMPENSATION & · INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE · Outstanding Equity Awards as of December 31, 2025
- 0001193125-25-139150
- 0000950170-25-059322Summary Compensation Table
- 0001193125-24-158461
- 0000950170-23-026351
- 0001193125-22-181461
- 0001193125-21-186845
- 0001193125-20-174063
- 0001193125-19-186073
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Atara Biotherapeutics executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/ATRA (accessed 2026).
Short form: data: Velarion
The Atara Biotherapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Atara Biotherapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}